Glycemic Control and Osteohealth in Adults Living With Type 1 Diabetes - Trial NCT06158503
Access comprehensive clinical trial information for NCT06158503 through Pure Global AI's free database. This phase not specified trial is sponsored by Centre hospitalier de l'Université de Montréal (CHUM) and is currently Not yet recruiting. The study focuses on Type 1 Diabetes. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Centre hospitalier de l'Université de Montréal (CHUM)
Timeline & Enrollment
N/A
Jan 01, 2024
Jun 30, 2027
Primary Outcome
Bone remodeling improvement
Summary
Bone damage is frequently observed in type 1 diabetes, and hyeprglycemia is associated with
 an increased risk of fracture. This pilot study in 25 people living with type 1 diabetes aims
 to determine whether the introduction of an automated insulin delivery (AID) system improves
 bone markers through rapide optimization of glycemic control. Measurements will be taken
 before the start of AID, 2 months and 4 months afterwards.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06158503
Device Trial